One major biotech investor just walked away from Viking Therapeutics. Here’s what the move may—and may not—mean for the ...

Traders floated scenarios ranging from a $20 billion buyout to a potential partnership with UnitedHealth, reviving Viking’s ...

Shares of biopharma company Viking Therapeutics ($VKTX) rose as high as 5% during the first hour of trading on Monday. The ...

Viking Therapeutics (VKTX) shares have seen some interesting moves over the past month, climbing more than 16%. Investors are watching closely, with a particular focus on how the biotech’s pipeline ...

Viking Therapeutics' stock initially surged after positive Phase 2 data for its obesity drug, but fell after Novo Nordisk shared data on a new, oral weight loss drug. Eli Lilly and Novo Nordisk have ...

After navigating a challenging period, Viking Therapeutics shares are demonstrating renewed vigor with a notable 16.6% advance over the past month. This upward movement suggests a potential shift in ...

The weight loss drug company was counted out far too early in the summer, but investors are warming to it again.

Major U.S. indices closed mixed on Tuesday, with the Dow Jones Industrial Average climbing 1.2% to 47,927.96 and the S&P 500 ...

The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at ...

Viking Therapeutics captured investor attention with compelling new research findings for its obesity treatment candidate VK2735. The biopharmaceutical company unveiled detailed results from its ...

Liver fibrosis is a growing global concern, driven by chronic conditions like hepatitis, obesity, and alcohol use. This progressive liver disease, marked by scar tissue buildup, can advance to ...

CINCINNATI, Aug. 5, 2025 /PRNewswire/ -- Viking Partners, a private real estate investment firm, closed on a $50.4 million acquisition of a 409,000-square-foot portfolio of small-bay industrial assets ...